Press Releases 2015


 
2015 | 2014 | 2013 | 2012
DateTitle 
March 02, 2015Incyte Appoints Steven H. Stein, MD as Chief Medical Officer
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’s extensive oncology portfolio. Steve... 
Printer Friendly Version
February 26, 2015Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer
Results expected to provide better strategies for both patients and physicians to manage the burden of this disease WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 26, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it is sponsoring the first major observational study of patients living with polycythemia vera (PV) in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, ... 
Printer Friendly Version
February 23, 2015Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study
INDIANAPOLIS, Feb. 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional ... 
Printer Friendly Version
February 17, 2015Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 17, 2015-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March: Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 10:40 am (EST) in Boston; and Barclays Global Healthcare Conference on Wednesday, March 11, 2015 at 3:50 pm (EDT) in Miami The prese... 
Printer Friendly Version
February 12, 2015Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs
$106 million of 2014 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 46 percent growth over the same period last year $358 million of 2014 full-year net product revenues from Jakafi, representing 52 percent growth over last year 2015 guidance for Jakafi net product revenues in the range of $525 million to $565 million, reflecting continued growth in underlying demand in mye... 
Printer Friendly Version
January 28, 2015Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine
Data show Jakafi® (ruxolitinib) was superior to standard therapy; resulting in durable hematocrit control, spleen volume reduction and complete hematological remission in patients with uncontrolled polycythemia vera (PV)1 PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack2 Jakafi® was recently appr... 
Printer Friendly Version
January 27, 2015Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, February 12, 2015. The schedule for the press release and conference call is as follows:         ... 
Printer Friendly Version
January 23, 2015Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 23, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it has earned a $25 million milestone payment from Novartis. This payment was triggered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopting a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyu... 
Printer Friendly Version
January 09, 2015Incyte Board Appoints Two New Directors
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 9, 2015-- Incyte Corporation (Nasdaq: INCY) today announced the appointment of Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin Pharmaceutical Inc., and Paul J. Clancy, Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc., as new Directors. The appointments are effective January 20, 2015. “The Incyte board welcomes Jean-Jacques and Paul as their extensive and re... 
Printer Friendly Version
January 09, 2015Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3 Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies Agenus to receive $60 million comprised of a $25 million technology and program access fee under the collaboration plus $35 million equity investment in Agenus at $4.51/share Agenus eligible to receive up to $350 million in development, regulatory and commercial... 
Printer Friendly Version